Baillie Gifford & Co. Sells 990,958 Shares of Moderna, Inc. (NASDAQ:MRNA)

Baillie Gifford & Co. trimmed its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 2.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,458,083 shares of the company's stock after selling 990,958 shares during the period. Moderna makes up about 2.1% of Baillie Gifford & Co.'s holdings, making the stock its 15th biggest position. Baillie Gifford & Co. owned approximately 11.05% of Moderna worth $2,837,474,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of MRNA. Vanguard Group Inc. increased its position in shares of Moderna by 15.1% during the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company's stock worth $4,159,769,000 after acquiring an additional 5,129,800 shares during the last quarter. Capital World Investors raised its stake in Moderna by 0.5% during the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company's stock valued at $388,743,000 after acquiring an additional 18,728 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Moderna by 2.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company's stock valued at $169,542,000 after buying an additional 29,566 shares during the period. ARK Investment Management LLC lifted its position in Moderna by 10.4% in the third quarter. ARK Investment Management LLC now owns 1,163,946 shares of the company's stock worth $77,787,000 after purchasing an additional 109,852 shares during the period. Finally, National Pension Service lifted its holdings in Moderna by 10.3% in the 3rd quarter. National Pension Service now owns 813,893 shares of the company's stock valued at $54,392,000 after acquiring an additional 75,817 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the company's stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company's stock, valued at $682,754. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,930 shares of company stock worth $217,170 in the last quarter. Insiders own 15.70% of the company's stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research reports. Oppenheimer lowered Moderna from an "outperform" rating to a "market perform" rating in a research report on Friday, September 13th. TD Cowen dropped their price objective on Moderna from $70.00 to $60.00 and set a "hold" rating for the company in a research note on Friday, September 13th. UBS Group reduced their target price on shares of Moderna from $140.00 to $108.00 and set a "buy" rating on the stock in a research note on Thursday, October 24th. Jefferies Financial Group decreased their price objective on shares of Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research note on Tuesday, October 15th. Finally, HSBC upgraded shares of Moderna from a "reduce" rating to a "hold" rating and set a $82.00 target price for the company in a research note on Wednesday, August 28th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $93.18.

Moderna Trading Down 0.1 %

NASDAQ MRNA traded down $0.06 during mid-day trading on Tuesday, reaching $42.69. 6,067,825 shares of the stock were exchanged, compared to its average volume of 4,548,393. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 3.92. The stock has a market cap of $16.41 billion, a P/E ratio of -7.33 and a beta of 1.69. The stock has a 50 day simple moving average of $61.15 and a 200-day simple moving average of $98.65. Moderna, Inc. has a one year low of $41.77 and a one year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.39) earnings per share. On average, analysts anticipate that Moderna, Inc. will post -9.89 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.